Skip to main content

Recursion Pharmaceuticals, Inc.

corporate_fare Company Profile

Recursion Pharmaceuticals, Inc.

RXRX·NASDAQ·Life Sciences·CIK 0001601830

Recursion is a clinical-stage TechBio company focused on decoding biology to improve lives. The company uses its integrated drug discovery and development platform, the Recursion Operating System (OS), to power its internal programs and strategic partnerships. This platform offers complete, AI-native capabilities from new biological ideas through clinical development, combining multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development. Recursion's technologies are designed to translate complex science into medicines more quickly, effectively, and at scale. Historically, moving a drug discovery project from early discovery to an approved therapeutic has taken over ten years and an average capitalized R&D cost of approximately $2-3.5 billion, with less than 4% of initiated programs resulting in an approved medicine. Recursion aims to transform this traditional "V-shaped" discovery funnel into a 'T-shaped' model by using advanced computational tools across biology, chemistry, and clinical development. The goal is to quickly narrow a broad set of potential medicines to candidates with the highest probabilities of success, moving programs through development more efficiently and with less attrition. Advances in artificial intelligence and machine learning (AI/ML) are increasingly influencing the technology and biopharmaceutical industries, with a majority of large biopharmaceutical companies now using AI/ML in drug discovery or development. Global investment in AI-enabled drug discovery has grown to several billions of dollars annually. Regulators and policymakers are also actively engaged, with AI/ML-enabled approaches applied across multiple stages of drug discovery and development, including target identification, molecular design, chemical synthesis, clinical development, and manufacturing.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for RXRX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Annual Report Reveals Deepening Losses, Critical Control Weaknesses, and New $300M Dilutive Offering
  • Recursion Achieves First AI-Driven Clinical Validation, Extends Cash Runway to Early 2028

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$74.68M
Net Income
-$644.76M
Diluted EPS
-$1.44
Op. Cash Flow
-$371.81M
Free Cash Flow
-$378.28M
Gross Profit
$3.73M
Operating Income
-$648.13M
Cash & Equivalents
$743.29M
Debt / Equity
0.00×
Net Margin
-8.63×
Shares Outstanding
528.18M sh
Source: 10-K · filed 2026-02-25 · accession 0001601830-26-000039
$2.51 +2.39% today
52-week range · as of 2026-11-02 $2.51 – $5.76
Market cap
$1.53B
Volume
29.9M (1.2× avg)
3-mo avg 25.6M
Live data · 2026-11-22 05:51 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RXRX - Filings & News (Page 2)

RXRX
Feb 25, 2026, 6:33 AM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $3.85
Real-time Price: $2.51 info
Change: -$1.34 (-35%) info
Market Cap: $1.527B info
RXRX
Feb 25, 2026, 6:31 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.77
Real-time Price: $2.51 info
Change: -$1.26 (-33%) info
Market Cap: $1.527B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets